These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Metastatic prostate cancer presenting as an asymptomatic neck mass. Carleton J, van der Riet P, Dahm P. Prostate Cancer Prostatic Dis; 2005; 8(3):293-5; discussion 295. PubMed ID: 15897914 [Abstract] [Full Text] [Related]
24. [A case of brain metastasis associated with prostate cancer]. Soga N, Sugimura Y. Hinyokika Kiyo; 2004 Jan; 50(1):37-40. PubMed ID: 15032014 [Abstract] [Full Text] [Related]
25. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [Abstract] [Full Text] [Related]
26. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F. Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361 [Abstract] [Full Text] [Related]
31. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group. BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622 [Abstract] [Full Text] [Related]
36. Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma. Kabeer MA, Lloyd-Davies E, Maskell G, Hohle R, Mathew J. World J Surg Oncol; 2007 Jan 07; 5():2. PubMed ID: 17207288 [Abstract] [Full Text] [Related]
37. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. J Urol; 2007 Sep 07; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [Abstract] [Full Text] [Related]
38. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. J Urol; 2008 Nov 07; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [Abstract] [Full Text] [Related]
39. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Can J Urol; 2009 Oct 07; 16(5):4806-12. PubMed ID: 19796455 [Abstract] [Full Text] [Related]
40. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Iversen P, Roder MA. Expert Rev Anticancer Ther; 2008 Mar 07; 8(3):361-9. PubMed ID: 18366284 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]